Sign in
Taking people in United StatesPhase 2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Key facts

Who runs it
Paul Szabolcs
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
25 people, planned
Started
4 May 2026
Expected to end
1 Feb 2031
Type of study
Interventional
Treatments tested
  • Hematopoietic stem cell transplant (HSCT)
Record updated
15 May 2026

Who can take part

Age
5 years to 40 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patient, parent, or legal guardian must have given written informed consent. For pediatric subjects who are developmentally able, assent or affirmation will be obtained
  • Male or female, 5 through 40 years old, inclusive, at the time of informed consent
  • Patients must have evidence of common variable immunodeficiency (CVID) or other autoimmune manifestation of a primary immune regulatory disorder (PIRD). Genetic screening is required by a targeting gene panel to determine presence of genetic variations that may lead to inborn errors of immunity; Examples of such diseases include, but are not limited to:; Common variable immunodeficiency (CVID); Combined Immunodeficiency (CID); Immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX syndrome), IPEX like syndromes; Combined immunodeficiency with defects in T-cell-mediated immunity, including Omenn syndrome and DiGeorge Syndrome; Chronic Granulomatous Disease (CGD); Signal Transducer and Activator of Transcription (STAT 1) Gain of Function (STAT1 GOF); Signal Transducer and Activator of Transcription (STAT 3) Gain of Function (STAT3 GOF); Hypomorphic Recombination-Activating Genes (RAG) 1 and RAG 2; CD40 or CD40L deficiency; Mendelian Susceptibility to Mycobacterial Disease; GATA-binding factor 2 (GATA2) Associated Immunodeficiency; Mouth and Genital Ulcers with Inflamed Cartilage Syndrome (MAGIC)
  • Must have previously failed, due to lack of response or intolerance, mycophenolate mofetil and a B cell-depleting antibody, such as Rituximab
  • Glomerular Filtration Rate (GFR) ≥50 mL/min/1.73 m2
  • Aspartate Aminotransferase (AST) ≤4x upper limit of normal
  • Alanine Aminotransferase (ALT) ≤4x upper limit of normal
  • Direct bilirubin ≤ 2.5 mg/dL
  • Human Immunodeficiency Virus (HIV) negative by serology and PCR
  • Human T-cell Lymphotropic Virus (HTLV) negative by serology
  • Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%
  • Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) ≥40% predicted for age
  • Peripheral Capillary Oxygen Saturation (SpO2) of >92% at rest on room air
  • Subjects must be a minimum of 8 weeks post-solid organ transplant prior to start of conditioning, if applicable
  • Negative pregnancy test for females >10 years old or who have reached menarche, unless surgically sterilized
  • All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 12 months after stem cell transplant or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defects
  • Subject and/or parent guardian informed of the potential risks of infertility following stem cell transplant and advised to discuss sperm banking or oocyte harvesting
  • Transplant endorsement from clinical immunologist

Who cannot take part

  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of stem cell transplant
  • Allergy to Dimethylsulfoxide (DMSO) or any other ingredient used in the manufacturing of the stem cell product
  • Uncontrolled systemic infection, as determined by the appropriate confirmatory testing e.g. blood cultures, Polymerase chain reaction (PCR) testing, etc
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 5 and 40 years old?

This trial is currently available in United States.

  • UPMC Children's Hospital of PittsburghPittsburgh, United StatesContact: Shawna McIntyreTaking people

About the trial

What the trial wants to find out

This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD).

The group in the trial

  • Hematopoietic stem cell transplant (HSCT)Other group

    The participant will receive an allogenic, fully (8 of 8 match) or partially HLA-matched (6-7/8 HLA-matched), stem cell transplant utilizing a conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07284641, who can take part
Record updated
15 May 2026